Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Ideaya Biosciences
Biotech
Ideaya pushes ahead with Biocytogen bispecific ADC bet
Biocytogen will receive a $6.5 million option payment and brings closer the potential for up to $400 million in milestone payments.
James Waldron
Nov 11, 2024 8:50am
Black Diamond, Ideaya mull registrational trials for cancer meds
Sep 23, 2024 12:18pm
Ideaya bags option on Biocytogen bispecific ADC in $400M deal
Jul 31, 2024 9:04am
Roche, Vir, Neurocrine & more—Chutes & Ladders
May 31, 2024 8:30am
GSK turns down one solid tumor collaboration with Ideaya
Aug 15, 2022 8:50am
Ideaya, Spelman team up to provide a steppingstone to biotech
Jan 19, 2021 1:07pm
